NCT02323607 - Pacritinib and Chemotherapy in Treating Patients With Acute Myeloid Leukemia and FLT3 Mutations | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 12, 2016

Primary Completion Date

July 12, 2018

Study Completion Date

July 12, 2018

Conditions

Recurrent Adult Acute Myeloid LeukemiaSecondary Acute Myeloid LeukemiaTherapy-Related Acute Myeloid LeukemiaUntreated Adult Acute Myeloid Leukemia

Interventions

DRUG

Pacritinib

Given PO

DRUG

Cytarabine

Given IV

DRUG

Daunorubicin Hydrochloride

Given IV

DRUG

Decitabine

Given IV

OTHER

Laboratory Biomarker Analysis

Correlative studies

OTHER

Pharmacological Study

Correlative studies

Trial Locations (1)

Arthur G. James Cancer Hospital and Solove Research Institute at Ohio State University Medical Center, Columbus